BM-02

Beyond Daily Eye Drops

Long-Acting Drug Delivery for Dry Eye Disease

An early-stage ophthalmic product opportunity with a milestone-driven development pathway.

Contact BD About This Program

Rethinking Long-Term Dry Eye Treatment

Dry eye disease frequently requires ongoing treatment, often involving repeated self-administration of topical medications.

For pharmaceutical companies, this creates an opportunity to explore a differentiated treatment model: sustained local ocular therapy designed to reduce reliance on frequent drug administration.

BM Pharma is investigating an innovative long-acting ocular delivery concept with the goal of enabling a more convenient, clinician-managed treatment approach.

Multi-month delivery is a development objective, subject to experimental and clinical validation.

The Product Opportunity

Our program explores an alternative to conventional eye-drop delivery through controlled and sustained local drug administration.

The development strategy focuses on three potential sources of product value:

1. Treatment Convenience

Explore whether sustained delivery could reduce the burden of repeated administration.

2. Product Differentiation

Investigate a differentiated ophthalmic product concept with a potentially distinct clinical and commercial profile.

3. Milestone-Driven Development

Advance the program through measurable technical and preclinical milestones, allowing partners to evaluate investment decisions as evidence develops.

Building Evidence That Matters

The feasibility program will focus on four critical questions:

Delivery-System Performance

Can the system maintain reliable local retention and predictable drug release?

Ocular Exposure and Tolerability

Can sustained delivery achieve relevant local exposure with acceptable ocular compatibility?

Drug-Specific Therapeutic Contribution

Can the active drug demonstrate meaningful effects beyond those attributable to the delivery system alone?

Clinical and Commercial Translation

Can the approach offer a practical treatment pathway with a compelling benefit–risk and treatment-burden profile?

Current Development Stage

Early-Stage R&D | Feasibility Validation

The program has a defined development concept and a proposed technical evaluation framework.

Key delivery-performance, pharmacokinetic, safety and therapeutic questions remain subject to experimental validation.

The next development phase is intended to generate decision-grade evidence to support candidate selection and further preclinical development.

Partnering Opportunity

BM Pharma invites discussions with ophthalmology-focused pharmaceutical companies interested in differentiated dry eye product opportunities.

Potential collaboration structures include funded feasibility evaluation, milestone-driven co-development, and technology licensing and regional development rights, subject to agreement.

Partners may participate early in shaping the development strategy, with subsequent investment decisions linked to predefined scientific and technical milestones.

Explore a Partnership

Contact BD About This Program

Detailed formulation, intellectual property and supporting technical information will be made available through an appropriate confidential partnering process.

This is an investigational development program. Target delivery duration, clinical efficacy, safety, and reduced dosing frequency have not been established.

Licensing & Co-Development

Our Integrated Licensing & Co-Development Model

One integrated agreement encompassing all four components

  1. Funded Feasibility Evaluation

  2. Technology Licensing

  3. Milestone Payments

  4. Sales-Based Royalties

Amounts, payment milestones, continued-development obligations and exit conditions are determined by the parties’ definitive agreement.

Contact BD About This Program

How to Start a Partnership

  1. 1. Introduce Your Company

    Email our Business Development team with a brief company introduction and the program of interest.

  2. 2. BD & Scientific Discussion

    Our BD team will coordinate an introductory discussion and involve relevant scientific or development specialists as appropriate.

  3. 3. Confidential Technical Review

    Following mutual interest, the parties may enter into a confidentiality agreement and exchange detailed technical information.

  4. 4. Integrated Partnership Agreement

    Potential collaboration is structured around funded feasibility evaluation, technology licensing, milestone payments and sales-based royalties under an integrated agreement.